



an Akzo Nobel company

Press release

Intervet International bv

Wim de Körverstraat 35

P.O. Box 31

5830 AA Boxmeer

Tel. +31 485 58 7600

Fax +31 485 57 7333

www.intervet.com

Foot-and-Mouth disease vaccine factory now owned by Intervet

Boxmeer, July 05, 2006 – Five months after signing an agreement on sale and purchase the Foot-and-Mouth (FMD) vaccine factory in Cologne Bayer HealthCare AG and Intervet International bv have completed the acquisition. Both parties have agreed not to disclose financial details.

As of July 4, 2006 Intervet, internationally market leader in Animal Health vaccines, is responsible for managing the FMD factory. The site will become Intervet's international competence centre for FMD vaccine production, development and research and will serve the needs from the markets for safe and efficacious FMD vaccines. In addition to this, the factory will also engage in antigen banks, which can, under governmental contracts, guarantee emergency supply of vaccines. By acquiring the Cologne factory Intervet substantially strengthens its worldwide position in the field of Foot-and-Mouth disease vaccines.

Note for the editor

Intervet, a business unit of Akzo Nobel, based in Boxmeer, the Netherlands, with sales of EUR 1,094 million in 2005, is dedicated to research and development, production and marketing of innovative animal health products. Intervet's product range for use in livestock, companion animals, poultry and fish includes vaccines, antiparasitics, anti-infectives, endocrine products and other pharmaceutical specialties. Intervet operates globally with its own marketing organizations. The company currently employs around 5,000 people.

Internet: www.intervet.com

Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 61,500 people and conduct our activities in four segments – human and animal health, coatings and chemicals – subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the second quarter will be published on July 20, 2006.

Internet: www.akzonobel.com

Not for publication – for more information

Sabine Schueller
Communications & Public Affairs
Intervet International bv

Tel: +31 (0)485 587085
Fax: +31 (0)485 585392
communications@intervet.com





Akzo Nobel Safe Harbor Statement applies to this press release.

*Safe Harbor Statement**

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the "Outlook", should be carefully considered and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more complete discussion of the risk factors affecting our business please refer to our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company's website www.akzonobel.com.

- Pursuant to the U.S. Private Securities Litigation Reform Act 1995.